Przejdź do zawartości
Merck

Novel Coumarin-Pyridine Hybrids as Potent Multi-Target Directed Ligands Aiming at Symptoms of Alzheimer's Disease.

Frontiers in chemistry (2022-07-19)
Elaheh Babaei, Tuba Tüylü Küçükkılınç, Leili Jalili-Baleh, Hamid Nadri, Esin Öz, Hamid Forootanfar, Elaheh Hosseinzadeh, Tayebeh Akbari, Mehdi Shafiee Ardestani, Loghman Firoozpour, Alireza Foroumadi, Mohammad Sharifzadeh, Bi Bi Fatemeh Mirjalili, Mehdi Khoobi
ABSTRAKT

In this research, a series of coumarin-based scaffolds linked to pyridine derivatives via a flexible aliphatic linkage were synthesized and assessed as multifunctional anti-AD agents. All the compounds showed acceptable acetylcholinesterase (AChE) inhibition activity in the nanomolar range (IC50 = 2-144 nM) and remarkable butyrylcholinesterase (BuChE) inhibition property (IC50 = 9-123 nM) compared to donepezil as the standard drug (IC50 = 14 and 275 nM, respectively). Compound 3f as the best AChE inhibitor (IC50 = 2 nM) showed acceptable BuChE inhibition activity (IC50 = 24 nM), 100 times more active than the standard drug. Compound 3f could also significantly protect PC12 and SH-SY5Y cells against H2O2-induced cell death and amyloid toxicity, respectively, superior to the standard drugs. It could interestingly reduce β-amyloid self and AChE-induced aggregation, more potent than the standard drug. All the results suggest that compound 3f could be considered as a promising multi-target-directed ligand (MTDL) against AD.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Acetylcholinesterase human, recombinant, expressed in HEK 293 cells, lyophilized powder, ≥1,000 units/mg protein (Lowry)
Sigma-Aldrich
Amyloid β Protein Fragment 1-42